Sprycel Side Effect Injury Lawsuits. October 11, 2011: The FDA has issued a Drug Safety Communication notifying healthcare professionals that Sprycel use may increase the risk of a rare but serious condition called Pulmonary Ateriral Hypertension or (PAH), which is an abnormally high blood pressure in the arteries of the lungs. The leukemia drug Sprycel […]
Sprycel Side Effect Injury Lawsuits. October 11, 2011: The FDA has issued a Drug Safety Communication notifying healthcare professionals that Sprycel use may increase the risk of a rare but serious condition called Pulmonary Ateriral Hypertension or (PAH), which is an abnormally high blood pressure in the arteries of the lungs.
The leukemia drug Sprycel (dasatinib) has been associated with pulmonary arterial hypertension (PAH), a potentially fatal condition. Between June 2006 and June 2011, 60 cases of serious pulmonary hypertension were reported worldwide, including 12 cases of confirmed PAH, in association with Sprycel treatment. If you or a loved one developed PAH while being treated with Sprycel, you may be entitled to compensation.
Lawyers at Parker Waichman LLP who specialize in defective drug litigation are investigating potential Sprycel lawsuits on behalf of PAH victims. Our Sprycel lawyers are currently offering free lawsuit evaluations to anyone who developed PAH while being treated with this drug. If you or a loved one were diagnosed with PAH while undergoing leukemia therapy with Sprycel, we urge you to contact our Sprycel lawyers today to protect your legal rights.
Sprycel is used to treat adult patients with a particular form (Philadelphia chromosome positive or Ph +) of newly diagnosed chronic myeloid leukemia (CML). It is also used to treat adult patients who have the same condition or acute lymphoblastic leukemia (ALL) showing resistance or intolerance to previous therapies. It belongs to a class of drugs called protein-tyrosine kinase inhibitors.
According to an alert issued by Health Canada in August 2011, 60 cases of serious pulmonary hypertension were reported worldwide among Sprycel patients, including 12 cases of confirmed PAH, between June 2006 and June 2011. Pulmonary hypertension is increased blood pressure in the pulmonary arteries, which carry blood from the heart to the lungs to pick up oxygen. PAH, a subtype of pulmonary hypertension, is a rare, severe and progressive disease with no apparent cause. PAH can lead to severe fluid retention in the body, shock and even death.
Signs and symptoms of PAH include:
Patients should contact their healthcare professional if they experience any of these signs and symptoms. Patients should tell their health-care professional if they have or have had any medical conditions, such as a heart problem and-or lung disease, before starting treatment with Sprycel.
The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).
